Your browser doesn't support javascript.
loading
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Pignon, Jean-Christophe; Jegede, Opeyemi; Shukla, Sachet A; Braun, David A; Horak, Christine E; Wind-Rotolo, Megan; Ishii, Yuko; Catalano, Paul J; Grosha, Jonian; Flaifel, Abdallah; Novak, Jesse S; Mahoney, Kathleen M; Freeman, Gordon J; Sharpe, Arlene H; Hodi, F Stephen; Motzer, Robert J; Choueiri, Toni K; Wu, Catherine J; Atkins, Michael B; McDermott, David F; Signoretti, Sabina.
Affiliation
  • Pignon JC; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Jegede O; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Shukla SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Braun DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Horak CE; Bristol-Myers Squibb, Princeton, New Jersey.
  • Wind-Rotolo M; Bristol-Myers Squibb, Princeton, New Jersey.
  • Ishii Y; Bristol-Myers Squibb, Princeton, New Jersey.
  • Catalano PJ; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Grosha J; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Flaifel A; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Novak JS; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mahoney KM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Sharpe AH; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Motzer RJ; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts.
  • Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Wu CJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Atkins MB; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • McDermott DF; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Signoretti S; Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia.
Clin Cancer Res ; 25(7): 2174-2184, 2019 04 01.
Article in En | MEDLINE | ID: mdl-30670497
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Biomarkers, Tumor / Antineoplastic Agents, Immunological / Nivolumab / Kidney Neoplasms Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Biomarkers, Tumor / Antineoplastic Agents, Immunological / Nivolumab / Kidney Neoplasms Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2019 Type: Article